

RECEIVED

JAN 2 9 2004

TECH CENTER 1600/2900

ATTORNEY DOCKET NO. 07180/004003

Certificate of Mailing: Date of Deposit: (20) 4

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Simmons

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Vassilis I. Zannis et al.

Art Unit:

1636

Serial No.:

09/827,854

Examiner:

Quang Nguyen

Filed:

April 5, 2001

Customer No.:

21559

Title:

COMPOUNDS AND METHODS FOR LOWERING

CHOLESTEROL LEVELS WITHOUT INDUCING

HYPERTRIGLYCERIDEMIA

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT</u>

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in

payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 20, 2004

Paul T. Clark Reg. No. 30,162

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045





SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERC (MODIFIED) PATENT AND TRADEMARK OFFIC				Attorney Docket No. Serial No.		07180/004003 09/827,854	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Filing Date		Vassilis I. Zannis et al. April 5, 2001	
				Group		1636	
				IDS Filed		January 20, 2004	
(37 C.F.R. § 1.98(b))				Customer No.		21559	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Patentee		Subclass	Filing Date (If Appropriate)
						-	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Country or Patent Office		Subclass	Translation (Yes/No)
							, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
							-
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
Chen et al., "Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low density lipoprotein receptor," <i>Molecular Therapy</i> 2:256-261 (2000).							
	Gerritsen et al., "Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain," <i>J. Lipid Research</i> 44:408-414 (2003).						
	Oka et al., "Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor," <i>Circulation</i> 103:1274-1281 (2001).						
		# -					
EXAMINER				ATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							